News

The first alpha particle-emitting radioactive therapeutic agent, Xofigo has been approved by the US Food and Drug Administration (FDA) to treat castration-resistant prostate cancer (CRPC), symptomatic bone metastases

Introduced by A*Star’s ICES, the new program offers a platform for pharma and specialty chemicals industry to deal with challenges, including costs, regulatory compliance and responsiveness in production

Conducted in the US at the University of California San Francisco, the University of Washington and the John Wayne Cancer Institute, the single-arm, open-label study will assess the

The main focus of this collaboration will be to recognize alternative therapeutic indications of marketed compounds for neglected and orphan diseases. In order to deal with the drug

The company has submitted a new drug application for the vaccine to the Ministry of Health, Labour and Welfare in Japan. In August 2011, the Ministry of Health,

Rapaflo is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH). The lawsuits were filed in the US District Court for the District of

As per the deal, both the companies will advance the product developement while ZMC will fund the ongoing development costs. ZMC will assume the commercialisation rights to the

The Phase IV SAVOR-TIMI-53 cardiovascular outcomes trial was conducted in 16,500 type 2 diabetes patients with either a history of established cardiovascular disease or multiple risk factors, with

Sources familiar with the matter were quoted by Reuters as saying that the $500m-$1bn worth portfolio could be divided and sold to different parties. Without disclosing the estimated